Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 4/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 12/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29074231 | 0.83 | LCK (0.52) | KDRLCKCDC7DBF4AURKA | |
| SCHEMBL14141947 | 0.81 | LCK (0.47) | LCKCDC7DBF4AURKAAURKB | |
| SCHEMBL1541108 | 0.80 | MAPT (0.65) | — | |
| SCHEMBL14460572 | 0.78 | NTRK1 (0.48) | KDRNTRK1CDK2METITK | |
| SCHEMBL525917 | 0.76 | RAB9A (0.50) | KDRLCKCDC7DBF4 | |
| SCHEMBL15541887 | 0.76 | ALDH1A1 (0.47) | LCKCDC7DBF4AURKAAURKB | |
| SCHEMBL27937292 | 0.75 | EGFR (0.53) | AURKAAURKB | |
| SCHEMBL21495194 | 0.74 | SIK2 (0.48) | LCKCDC7DBF4 | |
| SCHEMBL14141667 | 0.74 | LCK (0.47) | LCKCDC7DBF4AURKAAURKB | |
| SCHEMBL1539971 | 0.74 | LCK (0.81) | LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| EP-3222619-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2017-09-27 | — | — | EP | disclosed |
| EP-3222619-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-15 | — | — | US | disclosed |
| US-6979694-B2 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050261305-A1 | Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology | DAS JAGABANDHU | 2005-11-24 | — | — | US | disclosed |
| EP-1169038-A4 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004085388-A2 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | DAS JAGABANDHU (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | DAS JAGABANDHU (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | DAS JAGABANDHU (US) | 2004-02-05 | — | — | US | disclosed |
| EP-1169038-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000062778-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | LCK, SSB, JAK1 | KDR 2814/4885LCK 1/4885NTRK1 1012/4885 |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | KDR 844/4885LCK 1/4885NTRK1 728/4885 |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | JAK1, LCK, MERTK | KDR 1519/4885LCK 2/4885NTRK1 614/4885 |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | KDR 844/4885LCK 1/4885NTRK1 728/4885 |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | TPMT, JAK1, CHUK | KDR 2462/4885LCK 20/4885NTRK1 2156/4885 |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | KDR 844/4885LCK 1/4885NTRK1 728/4885 |
| US-20050261305-A1 | Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology | JAK2, JAK1, TYK2 | KDR 2620/4885LCK 11/4885NTRK1 498/4885 |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | LCK, ABL1, BTK | KDR 844/4885LCK 1/4885NTRK1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.